Medscape is available in 5 Language Editions – Choose your Edition here.


Premalignant Lesions of the Endometrium

  • Author: Jing Wang Chiang, MD; Chief Editor: Warner K Huh, MD  more...
Updated: May 13, 2016


Endometrial hyperplasia involves the proliferation of endometrial glands that results in a greater than normal gland-to-stroma ratio. This results in varying degrees of architectural complexity and cytologic atypia. The clinical significance of this diagnosis is progression to or concurrent endometrioid endometrial adenocarcinoma.  

Endometrial carcinoma is the most common gynecologic malignancy and the fourth most common cancer in women in the United States.  In 2016, the number of projected cases is 60,050 patients, leading to 10, 470 deaths.[1]   Significant morbidity or mortality can occur if endometrial hyperplasia is untreated with progression to cancer.  Accurate classification and diagnoses is key to guiding appropriate treatment. 

This article reviews the classification, pathophysiology, clinical features, and treatment of endometrial hyperplasia.

For other information, see Medscape's Ob/Gyn & Women's Health Specialty Center.


Background / Classification

Endometrial hyperplasia is believed to produce a continuum of lesions that may be the precursor to endometrial carcinoma of endometrioid histology.[2] The classification of endometrial hyperplasia has had numerous terminologies. The classification below is the most commonly used system and is used by the World Health Organization (WHO) and the International Society of Gynecologic Pathologists since 1994. This system characterizes the glandular architectural pattern as simple or complex and describes the presence or absence of nuclear atypia.

  • Simple hyperplasia - Increased number of glands but regular glandular architecture
  • Complex hyperplasia - Crowded irregular glands
  • Simple hyperplasia with atypia - Simple hyperplasia with presence of cytologic atypia (prominent nucleoli and nuclear pleomorphism)
  • Complex hyperplasia with atypia - Complex hyperplasia with cytologic atypia

The original retrospective study of 170 patients by Kurman et al found that lesions with varying degrees of complexity and presence of atypia, when left untreated for a mean of 13 years, progressed to adenocarcinoma at different rates. Simple hyperplasia was associated with a 1% rate of progression to cancer, complex hyperplasia 3% rate of progression, simple atypical hyperplasia 8% rate of progression, whereas complex atypical hyperplasia had a 29% rate of progression to cancer.[3]

Not only does the concern exist for atypical hyperplasia progressing to invasive cancer if untreated, but numerous studies found coexisting carcinoma at rates ranging from 17-56%.[4, 5, 6, 7, 8, 9, 10] A prospective Gynecologic Oncology Group study found that 306 patients with preoperative biopsies that diagnosed atypical endometrial hyperplasia had concurrent invasive adenocarcinoma in 42.6% of hysterectomy specimen.[11] Part of the difficulty in diagnosing concurrent carcinoma is due to lack of reproducibility in diagnosing hyperplasia, especially atypical hyperplasia versus adenocarcinoma among even expert gynecologic pathologists. Studies report only 40-69% interobserver agreement for hyperplasia or cancer.[12, 13, 14, 11]

Due to the poor reproducibility of diagnosis, gynecologic pathologists also proposed a simpler classification of endometrial hyperplasia (EH) versus endometrial intraepithelial neoplasia (EIN) using a computerized morphometric analysis. Endometrial Hyperplasia is benign hyperplasia and correlates closely to simple hyperplasia, whereas EIN is pre-malignant.  EIN is defined as when the volume of glandular crowding is greater than the stromal volume, the presence of cytologic alterations, a lesion larger than 1 mm, and exclusion of mimics or carcinoma. Classification as complex atypical hyperplasia (WHO system) or as EIN had similar sensitivities and negative predictive values for coexisting endometrial cancer.[15]   Others found the EIN classification to be better at predicting progression to cancer. Thus the ACOG and SGO Committee opinion recommend the use of EIN schema for a more clear terminology to distinguish premalignant lesions.[2, 16]  [17] ​  However, the WHO classification system remains the most commonly used and reported in existing literature. 



Endometrial hyperplasia results from continuous estrogen stimulation that is unopposed by progesterone. This can be due to endogenous estrogen or exogenous estrogenic sources. Endogenous estrogen may be caused by chronic anovulation associated with polycystic ovary syndrome (PCOS). Obesity also contributes to unopposed estrogen exposure due to chronic high levels of estradiol that result from aromatization of androgens in adipose tissue and conversion of androstenedione to estrone. Endometrial hyperplasia and cancer can also result from estradiol-secreting ovarian tumors such as granulosa cell tumors.

Exogenous unopposed estrogen without progesterone has been associated with increased endometrial hyperplasia and adenocarcinoma.[18] The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial found that unopposed estrogen exposure with 0.625 mg of conjugated equine estrogen replacement therapy increased the risk of complex hyperplasia by 22.7% and atypical hyperplasia by 11.8% over 3 years of use compared with a less than 1% increase in placebo controls.[19] The risk of endometrial cancer was not increased when 2.5 mg of medroxyprogesterone acetate was used in combination with 0.625 mg of conjugated equine estrogens in 8506 women in the Women's Health Initiative (WHI) study.[20] Tamoxifen, with its estrogenic effect on the endometrium, increases the risk of endometrial hyperplasia and endometrial cancer. The risk of progression to cancer is associated with an increased duration of use.[21]   While unopposed estrogen in oral contraceptive pills or estrogen replacement therapy increases the risk of hyperplasia and cancer, combination oral contraceptive pills and combination hormone replacement therapy does not increase and may decrease the risk of hyperplasia and cancer.

Other risk factors for endometrial hyperplasia are the same as those for type I endometrial adenocarcinoma, including obesity, nulliparity, early menarche, and late menopause. The independent risk factors for predicting when endometrial hyperplasia coexists with cancer include age older than 53 years, postmenopausal status, diabetes, abnormal bleeding, body mass index (BMI) of 27 or more, and atypical hyperplasia.[8]  

The exact mechanism of estrogen's role in the transformation of normal endometrium to hyperplasia and cancer is unknown. Genetic alterations are known to be associated with hyperplasia and type I endometrial cancers. Lesions with hyperplasia are associated with microsatellite instability and defects in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2) associated with the Lynch Syndrome.[22]  PTEN tumor suppressor gene mutations have also been found in 55% of hyperplasia cases and 83% of hyperplasia cases once it has progressed to endometrial cancer.[23]



Endometrial hyperplasia is most frequently diagnosed in postmenopausal women, but women of any age can be at risk if they are exposed to a source of unopposed estrogen. Endometrial hyperplasia is increasingly frequently seen in young women with chronic anovulation due to PCOS or obesity.



Clinical Features

The most common clinical presentation  of patients with endometrial hyperplasia is abnormal uterine bleeding, whether in the form of menorrhagia, metrorrhagia, or postmenopausal bleeding. It can be associated with uterine hemorrhage, requiring emergent medical or surgical interventions, loss of fertility, and blood transfusion therapy.  Others present with abnormal vaginal discharge or Pap smear results showing glandular abnormalities. The abnormal Pap smear result may be atypical glandular cells or presence of atypical endometrial cells.

When abnormal bleeding is present, a full history and physical examination is warranted with careful examination of the lower genital tract for lesions of the vulva, vagina, cervix, and palpation of uterus and ovaries. The source of vaginal discharge or bleeding, the size of the uterus and endometrial cavity, and any pelvic masses should be noted. If the patient is obese and a pelvic examination is inadequate, pelvic ultrasonography may be helpful to assess for ovarian masses. A diagnostic procedure is then needed to rule out hyperplasia or cancer if the patient is symptomatic or has abnormal cytology.

Diagnosis of endometrial hyperplasia is usually made by sampling the endometrial cavity with an endometrial biopsy in the office. Tissue sampling should be performed in women with risk factors who present with symptoms of abnormal vaginal bleeding or discharge. This includes women older than 35 years with abnormal bleeding, women younger than 35 years with bleeding and risk factors, women with persistent bleeding, and women with unopposed estrogen replacement, tamoxifen therapy, and HNPCC cancer syndrome.

In addition, a biopsy should be performed in women with atypical glandular cells (AGC) Pap smear or endometrial cells in Pap smears of women older than 40 years when out of synch with menstrual cycle.[24, 25] While no evidence of improved survival has been documented, some also advocate routine screening by endometrial biopsy in asymptomatic women with hereditary nonpolyposis colorectal cancer (HNPCC) syndrome or those on tamoxifen therapy. However, most of this high-risk population present with abnormal vaginal bleeding; thus, other experts recommend work-up only when symptoms are present.

If a patient does not tolerate an office biopsy or has cervical stenosis, endovaginal ultrasonography is an effective method to assess thickness of the endometrial echo complex and to evaluate uterine bleeding. Endovaginal ultrasonography has a sensitivity of greater than 96% for ruling out endometrial carcinoma if the endometrial echo complex is less than 5 mm. Persistent bleeding despite a thin stripe still warrants tissue biopsy because of the risk of missing a type 2 cancer that is not associated with hyperplasia and thickening of the endometrial echo complex.[26] If hyperplasia is diagnosed by office biopsy, one should consider D&C and hysteroscopy to more definitely rule out atypia or cancer prior to conservative medical management. This is because blind D&C and pipelle endometrial biopsies both sample only 50-60% of the endometrial cavity, and miss focal lesions.  [27]


Treatment & Management

The accurate diagnosis of hyperplasia type is vital for appropriate treatment based on risk of cancer without over or under treatment.  Once a tissue diagnosis of endometrial hyperplasia is made, treatment depends on degree of hyperplasia, the patient's symptoms such as severity of bleeding, surgical risks, and wish for future childbearing. Progestins can effectively treat endometrial hyperplasia to control bleeding and prevent progression to cancer. They can serve as prevention of recurrence in those with continued risk factors. Hyperplasia without atypia responds well to progestins. More than 98% of women with hyperplasia treated with cyclic progestins experienced regression of the disease in 3-6 months.[28]   However, atypical hyperplasia or EIN lesions should undergo hysterectomy if they have completed childbearing and are reasonable surgical candidates due to a 42% risk of concurrent endometrial cancer. [11]

The PEPI trial showed a 94% normalization of complex or atypical hyperplasia in 45 women treated with progestins.[19] One cohort study found that 115 patients with complex atypical hyperplasia had approximately 30% persistence or progression of disease whether treated with progestins or not. However, of 70 patients with atypical hyperplasia, 67% vs 27% had persistence or progression when not treated with progestins.[29]

Multiple regimens of progestin therapy have been found effective in reversing endometrial hyperplasia, including the following:[30]

  • Medroxyprogesterone acetate - MPA (Provera), 10-20 mg qd, or cyclic 12-14 days per month
  • Depot Medroxyprogesterone (Depo-provera)  150 mg IM q 3 months
  • Micronized vaginal progesterone (Prometrium), 100-200 mg qd or cyclic 12-14 days per month
  • Levonorgestrel-containing IUD (Mirena), 20 mcg/day  [31]
  • Megestrol acetate (Megace), 40-200 mg per day, usually reserved for women with atypical hyperplasia

If the patient has not completed childbearing or is not a surgical candidate, then concurrent cancer must first be ruled out by D&C with hysteroscopy prior to medical management.  We recommend megestrol acetate for atypical hyperplasia, with or without levonorgestrel IUD for patients wishing to preserve fertility or for those too ill for surgical management. Any progestin should be adequate for treatment of hyperplasia without atypia or for maintenance after resolution of atypical hyperplasia. Patient should be sampled to assess for response every 3 to 6 months for regression to normal endometrium.  If  there is inadequate response in 6 months, consider increasing dose or changing progestins.  There is no proven protocol for selection or dosing. Continued surveillance after regression of the lesion is recommended every 6-12 months if risk factors persist. Repeat biopsy is also indicated for recurrent abnormal bleeding or discharge. Prevention of recurrence include use of daily or cyclic progesterone, indwelling levonorgestrel IUD, along with weight loss for obese patients.

Due to the large number of young anovulatory women diagnosed with atypical hyperplasia or early endometrial cancer, numerous studies have examined the outcome of fertility-sparing hormonal therapy. A meta-analysis of 24 observational studies that included a total of 151 women with atypical hyperplasia found that those who had fertility-sparing treatments had 86% regression, 26% relapse, and live birth rate of 26%.[32]

Another review of complex atypical hyperplasia patients who underwent progestin therapy found a complete response rate of 66%. Median time to response was 6 months. Recurrence rate after initial response was 23%. During study follow-up time of 39 months, 41% of patients with atypical hyperplasia became pregnant.[33] Interest is increasing in the use of levonorgestrel-releasing intrauterine system (LNG-IUS) as a treatment option for endometrial hyperplasia to deliver local effect with less systemic side-effects.[34] A 15-year study using the LNG-IUS for 34 patients with endometrial hyperplasia found regression to atrophic endometrium in 94%. However, this study had only 4 (12%) patients with atypical hyperplasia.[35]   A meta-analysis of 24 observational studies, including 1,001 cases, indicate that progestins appeared to induce a lower disease regression rate than LNG-IUS in the treatment of complex and atypical endometrial hyperplasia. However, a controlled clinical trial is necessary to confirm the observational findings.[36] The authors feel data using the LNG-IUD as the only treatment modality for atypical hyperplasia or endometrial cancer are still limited.

As mentioned above, the Gynecologic Oncology Group pathologic study with biopsy diagnosis of atypical hyperplasia found 42.6% concurrent endometrial carcinoma on hysterectomy specimen; 31% of these had myometrial invasion, including 10.6% with outer half myometrial invasion.[11]  Others also found atypical endometrial hyperplasia on office biopsy or D&C was associated with a 48-56% cancer rate on permanent pathology. Thus, if a hysterectomy is planned for treatment of atypical hyperplasia based on office endometrial biopsy, the authors recommend having a gynecologic oncologist be primary surgeon, or be available for surgical staging if needed based on frozen section of uterine specimen.[10]  [27]   If a D&C with hysteroscopy had been performed to rule out concurrent carcinoma more definitively, oncology back-up is likely not needed.  Due to the risk of cancer, supracervical, morcellation, or endometrial ablation is not recommended.  While a simple hysterectomy is adequate for definitive treatment of hyperplasia, one can consider bilateral salpingo-oophorectomy in perimenopausal or postmenopausal women due to possibility of cancer on permanent section.  Ovaries should only be removed if cancer is diagnosed in premenopausal women.  They should be counseled a second surgery may be required to remove ovaries and perform lymph node staging if cancer if found on final pathology. 

The need for hysterectomy to exclude concurrent myoinvasive endometrioid adenocarcinoma presents a barrier to nonsurgical management of endometrial hyperplasia. A Gynecologic Oncology Group study examined the histomorphometric 4-class rule (4C), which measures epithelial abundance, thickness, and nuclear variation as applied to diagnostic biopsies to predict myoinvasive cancer outcomes at hysterectomy.[37] Women with endometrial biopsies or curettages with a community diagnosis of atypical endometrial hyperplasia were enrolled in a clinical trial in which subsequent hysterectomy was scored for endometrial adenocarcinoma, and 4C rule ability to predict cancer outcomes was measured.  Qualifying biopsies were stratified into high-risk and low-risk histomorphometric subgroups. Assignment to a high-risk category by 4C rule was highly sensitive in predicting any (71%) or deeply (92%) myoinvasive adenocarcinoma at hysterectomy, and assignment to a low-risk group had a high negative predictive value for absence of any (90%) or deeply (99%) myoinvasive disease.  At present, this use of histomorphometry is most suited to a centralized reference laboratory performing histomorphometry for a variety of diagnostic applications. However, in the future, formal histomorphometry of endometrial biopsies using the 4C rule may become a more common method to identify a subset of women with premalignant disease who are unlikely to have concurrent myoinvasive adenocarcinoma and therefore may qualify for nonsurgical therapy.

Contributor Information and Disclosures

Jing Wang Chiang, MD Clinical Associate Professor of Obstetrics and Gynecology (Affiliated), Stanford University School of Medicine; Chief of Gynecologic Oncology, Department of Obstetrics and Gynecology, Santa Clara Valley Medical Center

Jing Wang Chiang, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology

Disclosure: Nothing to disclose.


Nicole Wilcox, MD, MPH Staff Physician, Department of Obstetrics and Gynecology, Santa Clara Valley Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Chief Editor

Warner K Huh, MD Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Senior Scientist, Comprehensive Cancer Center, University of Alabama School of Medicine

Warner K Huh, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Surgeons, Massachusetts Medical Society, Society of Gynecologic Oncology, American Society of Clinical Oncology

Disclosure: I have received consulting fees for: Merck; THEVAX.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Susan B Tate, MD, and Charles N Landen, MD, to the development and writing of this article.

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan. 66 (1):7-30. [Medline].

  2. Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. 2015 May. 125 (5):1272-8. [Medline].

  3. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15. 56(2):403-12. [Medline].

  4. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982 Jun 15. 49(12):2547-59. [Medline].

  5. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol. 1994 Mar. 52(3):373-8. [Medline].

  6. Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol. 1996 May. 174(5):1518-21. [Medline].

  7. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004 Mar-Apr. 14(2):348-53. [Medline].

  8. Chen YL, Wang KL, Chen MY, et al. Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group. J Gynecol Oncol. 2013 Jan. 24(1):14-20. [Medline]. [Full Text].

  9. Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol. 2012 Nov. 36(11):1683-90. [Medline].

  10. Morotti M, Menada MV, Moioli M, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol. 2012 Jun. 125(3):536-40. [Medline].

  11. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15. 106(4):812-9. [Medline].

  12. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol. 1999 Sep. 23(9):1102-8. [Medline].

  13. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998 Aug. 22(8):1012-9. [Medline].

  14. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15. 106(4):804-11. [Medline].

  15. Salman MC, Usubutun A, Boynukalin K, Yuce K. Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. J Gynecol Oncol. 2010 Jun. 21(2):97-101. [Medline]. [Full Text].

  16. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol. 2000 Mar. 76 (3):287-90. [Medline].

  17. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 2005 Jun 1. 103 (11):2304-12. [Medline].

  18. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. 2004. CD000402. [Medline].

  19. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996 Feb 7. 275(5):370-5. [Medline].

  20. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1. 290(13):1739-48. [Medline].

  21. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004 Aug. 94(2):256-66. [Medline].

  22. Lancaster JM, Powell CB, Chen LM, Richardson DL, SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan. 136 (1):3-7. [Medline].

  23. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000 Mar. 13(3):295-308. [Medline].

  24. Wu HH, Schuetz MJ 3rd, Cramer H. Significance of benign endometrial cells in Pap smears from postmenopausal women. J Reprod Med. 2001 Sep. 46(9):795-8. [Medline].

  25. Siebers AG, Verbeek AL, Massuger LF, Grefte JM, Bulten J. Normal appearing endometrial cells in cervical smears of asymptomatic postmenopausal women have predictive value for significant endometrial pathology. Int J Gynecol Cancer. 2006 May-Jun. 16(3):1069-74. [Medline].

  26. Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol. 2006 Apr. 101(1):120-5. [Medline].

  27. Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol. 2009 Sep. 114(3):523-9. [Medline].

  28. Gambrell RD Jr. Progestogens in estrogen-replacement therapy. Clin Obstet Gynecol. 1995 Dec. 38(4):890-901. [Medline].

  29. Reed S, Voigt L, Newton K, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol. March 2009. 113:655-662.

  30. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol. 2012 Nov. 120 (5):1160-75. [Medline].

  31. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol. 2009 Jun. 49(3):316-22. [Medline].

  32. Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012 Oct. 207(4):266.e1-12. [Medline].

  33. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May. 125(2):477-82. [Medline].

  34. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014 Mar. 121(4):477-86. [Medline].

  35. Scarselli G, Bargelli G, Taddei GL, et al. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertil Steril. 2011 Jan. 95(1):420-2. [Medline].

  36. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Dec. 203(6):547.e1-10. [Medline]. [Full Text].

  37. Mutter GL, Kauderer J, Baak JP, Alberts D. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol. 2008 Jun. 39(6):866-74. [Medline]. [Full Text].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.